← vista completa

Publicado el 1 de diciembre de 2009 | http://doi.org/10.5867/medwave.2009.12.4314

Actualización en cestágenos y tibolona

Update on progestins and tibolone

Santiago Palacios

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Santiago Palacios

Instituto Palacios, Salud y Medicina de la Mujer, Madrid, España

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Palacios S. Update on progestins and tibolone. Medwave 2009;9(12):e4314 doi: 10.5867/medwave.2009.12.4314

Publicación 01/12/2009

Métricas del artículo

Artículo no tiene métricas.

Notas

Referencias

  1. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004 Jul;47(7):1175-87. Epub 2004 Jul 14. | PubMed
  2. Andersen LF, Gram J, Skouby SO, Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):283-9. | CrossRef | PubMed
  3. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007 Feb 20;115(7):840-5. | CrossRef | PubMed
  4. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007 Apr;10(2):120-31. | CrossRef | PubMed
  5. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):231-8. | PubMed
  6. Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005 May 16;51(1):21-8. | CrossRef | PubMed
  7. Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007 Mar;92(3):911-8. Epub 2006 Dec 27. | CrossRef | PubMed
  8. Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG. 2007 Dec;114(12):1522-9. | CrossRef | PubMed
  9. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008 Aug 14;359(7):697-708. | CrossRef | PubMed
  10. Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Nijland EA. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women Osteoporos Int. 2008 Aug;19(8):1153-60. Epub 2008 Feb 7. | CrossRef | PubMed
  11. Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, et al Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med. 2008 Mar;5(3):646-56. | CrossRef | PubMed
  12. Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Nijland EA. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women Osteoporos Int. 2008 Aug;19(8):1153-60. Epub 2008 Feb 7. | CrossRef | PubMed
  13. Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007 Mar;92(3):911-8. Epub 2006 Dec 27. | CrossRef | PubMed